Leung AY, Foster S. Encyclopedia of Common Natural Ingredients Used in Food, Drugs and Cosmetics. 2nd ed. New York, NY: John Wiley & Sons, 1996.
Electronic Code of Federal Regulations. Title 21. Part 182 -- Substances Generally Recognized As Safe. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=182
Fetrow CW, Avila JR. Professional's Handbook of Complementary & Alternative Medicines. 1st ed. Springhouse, PA: Springhouse Corp., 1999.
Carlucci, M. J., Scolaro, L. A., and Damonte, E. B. Inhibitory action of natural carrageenans on Herpes simplex virus infection of mouse astrocytes. Chemotherapy 1999;45(6):429-436.
Dumelod, B. D., Ramirez, R. P., Tiangson, C. L., Barrios, E. B., and Panlasigui, L. N. Carbohydrate availability of arroz caldo with lambda-carrageenan. Int.J.Food Sci.Nutr. 1999;50(4):283-289.
Coggins, C., Blanchard, K., Alvarez, F., Brache, V., Weisberg, E., Kilmarx, P. H., Lacarra, M., Massai, R., Mishell, D., Jr., Salvatierra, A., Witwatwongwana, P., Elias, C., and Ellertson, C. Preliminary safety and acceptability of a carrageenan gel for possible use as a vaginal microbicide. Sex Transm.Infect. 2000;76(6):480-483.
Maguire, R. A., Bergman, N., and Phillips, D. M. Comparison of microbicides for efficacy in protecting mice against vaginal challenge with herpes simplex virus type 2, cytotoxicity, antibacterial properties, and sperm immobilization. Sex Transm.Dis. 2001;28(5):259-265.
Tobacman, J. K., Wallace, R. B., and Zimmerman, M. B. Consumption of carrageenan and other water-soluble polymers used as food additives and incidence of mammary carcinoma. Med.Hypotheses 2001;56(5):589-598.
Tobacman, J. K. Review of harmful gastrointestinal effects of carrageenan in animal experiments. Environ.Health Perspect. 2001;109(10):983-994.
Bianchi, M. and Broggini, M. Anti-hyperalgesic effects of nimesulide: studies in rats and humans. Int J Clin.Pract.Suppl 2002;(128):11-19.
Flower, R. J., Harvey, E. A., and Kingston, W. P. Inflammatory effects of prostaglandin D2 in rat and human skin. Br.J Pharmacol. 1976;56(2):229-233.
Perotti, M. E., Pirovano, A., and Phillips, D. M. Carrageenan formulation prevents macrophage trafficking from vagina: implications for microbicide development. Biol.Reprod. 2003;69(3):933-939.
Panlasigui, L. N., Baello, O. Q., Dimatangal, J. M., and Dumelod, B. D. Blood cholesterol and lipid-lowering effects of carrageenan on human volunteers. Asia Pac.J.Clin.Nutr. 2003;12(2):209-214.
Carlucci, M. J., Scolaro, L. A., Noseda, M. D., Cerezo, A. S., and Damonte, E. B. Protective effect of a natural carrageenan on genital herpes simplex virus infection in mice. Antiviral Res. 2004;64(2):137-141.
Buck, C. B., Thompson, C. D., Roberts, J. N., Muller, M., Lowy, D. R., and Schiller, J. T. Carrageenan is a potent inhibitor of papillomavirus infection. PLoS.Pathog. 2006;2(7):e69.
Kilmarx, P. H., van de Wijgert, J. H., Chaikummao, S., Jones, H. E., Limpakarnjanarat, K., Friedland, B. A., Karon, J. M., Manopaiboon, C., Srivirojana, N., Yanpaisarn, S., Supawitkul, S., Young, N. L., Mock, P. A., Blanchard, K., and Mastro, T. D. Safety and acceptability of the candidate microbicide Carraguard in Thai Women: findings from a Phase II Clinical Trial. J Acquir.Immune.Defic.Syndr. 11-1-2006;43(3):327-334.
Whitehead, S. J., Kilmarx, P. H., Blanchard, K., Manopaiboon, C., Chaikummao, S., Friedland, B., Achalapong, J., Wankrairoj, M., Mock, P., Thanprasertsuk, S., and Tappero, J. W. Acceptability of Carraguard vaginal gel use among Thai couples. AIDS 11-14-2006;20(17):2141-2148.
Cummins, J. E., Jr., Guarner, J., Flowers, L., Guenthner, P. C., Bartlett, J., Morken, T., Grohskopf, L. A., Paxton, L., and Dezzutti, C. S. Preclinical testing of candidate topical microbicides for anti-human immunodeficiency virus type 1 activity and tissue toxicity in a human cervical explant culture. Antimicrob.Agents Chemother. 2007;51(5):1770-1779.
Watanabe, K., Reddy, B. S., Wong, C. Q., and Weisburger, J. H. Effect of dietary undegraded carrageenan on colon carcinogenesis in F344 rats treated with azoxymethane or methylnitrosourea. Cancer Res. 1978;38(12):4427-4430.
Ogino, M., Majima, M., Kawamura, M., Hatanaka, K., Saito, M., Harada, Y., and Katori, M. Increased migration of neutrophils to granulocyte-colony stimulating factor in rat carrageenin-induced pleurisy: roles of complement, bradykinin, and inducible cyclooxygenase-2. Inflamm.Res. 1996;45(7):335-346.
Zacharopoulos, V. R. and Phillips, D. M. Vaginal formulations of carrageenan protect mice from herpes simplex virus infection. Clin.Diagn.Lab Immunol. 1997;4(4):465-468.
Elias, C. J., Coggins, C., Alvarez, F., Brache, V., Fraser, I. S., Lacarra, M., Lahteenmaki, P., Massai, R., Mishell, D. R., Jr., Phillips, D. M., and Salvatierra, A. M. Colposcopic evaluation of a vaginal gel formulation of iota-carrageenan. Contraception 1997;56(6):387-389.
Eccles R, Meier C, Jawad M, Weinmüllner R, Grassauer A, Prieschl-Grassauer E. Efficacy and safety of an antiviral Iota-Carrageenan nasal spray: a randomized, double-blind, placebo-controlled exploratory study in volunteers with early symptoms of the common cold. Respir Res. 2010;11:108.
Eccles R, Winther B, Johnston SL, Robinson P, Trampisch M, Koelsch S. Efficacy and safety of iota-carrageenan nasal spray versus placebo in early treatment of the common cold in adults: the ICICC trial. Respir Res. 2015;16:121.
Fazekas T, Eickhoff P, Pruckner N, et al. Lessons learned from a double-blind randomised placebo-controlled study with a iota-carrageenan nasal spray as medical device in children with acute symptoms of common cold. BMC Complement Altern Med. 2012;12:147.
Ludwig M, Enzenhofer E, Schneider S, et al. Efficacy of a carrageenan nasal spray in patients with common cold: a randomized controlled trial. Respir Res. 2013;14:124.
Hebar A, Koller C, Seifert JM, et al. Non-clinical safety evaluation of intranasal iota-carrageenan. PLoS One. 2015;10(4):e0122911.
European Commission. Opinion of the Scientific Committee on Food on Carrageenan. Available at: https://ec.europa.eu/food/sites/food/files/safety/docs/sci-com_scf_out164_en.pdf
Electronic Code of Federal Regulations. Title 21, Chapter 1, Subchapter B, Part 172: food additives permitted for direct addition to food for human consumption. Available at: https://www.ecfr.gov/cgi-bin/text-idx?SID=59189f37d05de4dda57b07856d8d56f8&mc=true&node=pt21.3.172&rgn=div5#se21.3.172_1515
Paris quadrifolia L. U.S. National Plant Germplasm System. https://npgsweb.ars-grin.gov/gringlobal/taxonomydetail.aspx?id=410335. Accessed April 30, 2020.
Technical evaluation report: carrageenan. United States Department of Agriculture (USDA) National Organic Program. https://www.ams.usda.gov/sites/default/files/media/Carrageenan%20TR%202011.pdf. Published October 3, 2011. Accessed July 15, 2020.
Feferman L, Bhattacharyya S, Oates E, et al. Carrageenan-free diet shows improved glucose tolerance and insulin signaling in prediabetes: a randomized, pilot clinical trial. J Diabetes Res. 2020 Apr 21;2020:8267980. doi: 10.1155/2020/8267980.
Qiu X, Zhong W. Antihyperglycemic and antihyperlipidemic effects of low-molecular-weight carrageenan in rats. Open Life Sci. 2018;13:379-84.
Zhou J, Wang F, Chen J, et al. Long-term kappa-carrageenan consumption leads to moderate metabolic disorder by blocking insulin binding. Pharmacol Res. 2021 Mar;165:105417. doi: 10.1016/j.phrs.2020.105417.
Bhattacharyya S, Shumard T, Xie H, et al. A randomized trial of the effects of the no-carrageenan diet on ulcerative colitis disease activity. Nutr Healthy Aging. 2017;4(2):181-92.
Bhattacharyya S, Feferman L, Unterman T, Tobacman JK. Exposure to common food additive carrageenan alone leads to fasting hyperglycemia and in combination with high fat diet exacerbates glucose intolerance and hyperlipidemia without effect on weight. J. Diabetes Res. 2015;2015:513429.
Laurie C, El-Zein M, Tota JE, et al. Efficacy of a carrageenan gel in preventing anal human papillomavirus (HPV) infection: interim analysis of the Lubricant Investigation in Men to Inhibit Transmission of HPV Infection (LIMIT-HPV) randomised controlled trial. Sex Transm Infect 2021.
Figueroa JM, Lombardo ME, Dogliotti A, et al. Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Postexposure Prophylaxis of COVID-19 in Hospital Personnel Dedicated to Patients Care with COVID-19 Disease. Int J Gen Med 2021;14:6277-6286.
CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.
This copyrighted material is licensed from Therapeutic Research Center, LLC. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
Licensed from Therapeutic Research Center, LLC
Copyright © 1995-2025 by Therapeutic Research Center, LLC. All Rights Reserved.